Pfizer & BioNTech COVID-19 vaccine candidate achieves success in phase 3 study
The vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis